2-(环己基甲氧基)乙醇 | 88964-98-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-(环己基甲氧基)乙醇
• 英文名称: 2-(cyclohexylmethoxy)ethanol
• 英文别名: 2-cyclohexylmethoxy-ethanol；2-Cyclohexylmethoxy-aethanol；2-(Cyclohexylmethoxy)ethan-1-ol
• CAS: 88964-98-1
• 化学式: C₉H₁₈O₂
• 分子量: 158.241
• InChiKey: JCYRHSFSQOJYJD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(环己基甲氧基)乙醇 在 N-甲基吗啉 、 sodium azide 、 水 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 三苯基膦 作用下， 以 四氢呋喃 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 N-<2-(cyclohexylmethoxy)ethyl>-2-<4-(3-pyridylcarbonyl)phenyl>-4-oxazolecarboxamide
  参考文献：
  名称：

  Development of Dual-Acting Agents for Thromboxane Receptor Antagonism and Thromboxane Synthase Inhibition. 3. Synthesis and Biological Activities of Oxazolecarboxamide-Substituted ω-Phenyl-ω-(3-pyridyl)alkenoic Acid Derivatives and Related Compounds

  摘要：

  A novel series of oxazolecarboxamide-substituted omega-phenyl-omega-(3-pyridyl)alkenoic acid derivatives was discovered as potent dual-acting agents to block the TXA(2) receptor and to inhibit the thromboxane synthase (TRA/TSI). Synthesis, structure-activity relationship (SAR), and in vitro and in vivo pharmacology of this series of compounds are described. Modification of the series revolved around the oxazole moiety to increase the hydrophilicity of the compounds and to correlate the biological activity with lipophilicity of the compounds. The most potent in the series was (E)-7-[4-[4-[[(4-cyclohexylbutyl)amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoic acid (14) with K-d = 9.9 +/- 0.4 nM for the thromboxane receptor antagonism and IC50 = 55.0 +/- 17.9 nM for thromboxane synthase inhibition. The compound 14 was a selective TRA/TSI which exhibited desirable characteristics for oral activity, "shunt" effect to elevate PGI(2) level, and absence of agonist activity.

  DOI：

  10.1021/jm980173n
• 作为产物：
  描述：

  2-苄氧基乙醇 在 乙醚 、 镍 作用下， 生成 2-(环己基甲氧基)乙醇
  参考文献：
  名称：

  THE USE OF NICKEL AS A CATALYST FOR HYDROGENATION. II

  摘要：

  DOI：

  10.1021/ja01343a064

文献信息

• Potent α-amino-β-lactam carbamic acid ester as NAAA inhibitors. Synthesis and structure–activity relationship (SAR) studies
  作者：Andrea Nuzzi、Annalisa Fiasella、Jose Antonio Ortega、Chiara Pagliuca、Stefano Ponzano、Daniela Pizzirani、Sine Mandrup Bertozzi、Giuliana Ottonello、Glauco Tarozzo、Angelo Reggiani、Tiziano Bandiera、Fabio Bertozzi、Daniele Piomelli

  DOI：10.1016/j.ejmech.2016.01.046

  日期：2016.3

  2-oxo-3-azetidinyl ring as well as on the effect of size and shape of the carbamic acid ester side chain led to the discovery of 3ak, a novel inhibitor of human NAAA that shows an improved physicochemical and drug-like profile relative to 3b. This favourable profile, along with the structural diversity of the carbamic acid chain of 3b, identify this compound as a promising new tool to investigate the potential

  4-环己基丁基-N -[（S）-2-氧杂氮杂环丁-3-基]氨基甲酸酯（3b）是一种有效的，选择性的和系统性的细胞内NAAA活性抑制剂，可在动物模型中产生深远的抗炎作用。在当前的工作中，我们描述了对3-氨基氮杂环丁烷-2-one衍生物的结构-活性关系（SAR）研究，该研究导致了3b的鉴定，并扩展了这些研究以阐明获得有效的结构和立体化学特征。 NAAA抑制。关于2-氧代-3-氮杂环丁烷基环的β-位取代的影响以及氨基甲酸酯侧链的大小和形状的影响的研究导致了3ak的发现。，一种人类NAAA的新型抑制剂，相对于3b而言，它具有改善的理化和类药物特性。这种有利的特性以及3b氨基甲酸酯链的结构多样性，使该化合物成为研究NAAA抑制剂作为治疗疼痛和炎症的潜力的有前途的新工具。
• CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS
  申请人：The Regents of the University of California

  公开号：US20160068482A1

  公开（公告）日：2016-03-10

  Described herein are compounds and pharmaceutical compositions which inhibit N-acylethanolamine acid amidase (NAAA). Described herein are methods for synthesizing the compounds set forth herein and methods for formulating these compounds as pharmaceutical compositions which include these compounds. Also described herein are methods of inhibiting NAAA in order to sustain the levels of palmitoylethanolamide (PEA) and other N-acylethanolamines (NAE) that are substrates for NAAA, in conditions characterized by reduced concentrations of NAE. Also, described here are methods of treating and ameliorating pain, inflammation, inflammatory diseases, and other disorders in which modulation of fatty acid ethanolamides is clinically or therapeutically relevant or in which decreased levels of NAE are associated with the disorder.

  本文描述了一些化合物和药物组成物，它们可以抑制N-酰基乙醇胺酸酰化酶（NAAA）。本文还描述了合成这些化合物的方法，以及将它们制成药物组成物的方法。同时，本文还描述了抑制NAAA以维持棕榈酰乙醇胺（PEA）和其他N-酰基乙醇胺（NAE）的水平的方法，这些物质是NAAA的底物，并且在NAE浓度降低的情况下有用。此外，本文还描述了治疗和缓解疼痛、炎症、炎症性疾病和其他疾病的方法，这些疾病中脂肪酸乙醇胺的调节在临床或治疗上是相关的，或者NAE的浓度降低与该疾病有关。
• PROCESS FOR ALKYLATING TRIAZINE DERIVATIVE
  申请人：NISSAN CHEMICAL INDUSTRIES, LIMITED

  公开号：EP0760369A1

  公开（公告）日：1997-03-05

  The object of the present invention is to provide a method for producing substituted-1,3,5-triazine derivatives at high yield, in which at least one of carbon atoms in the ring thereof is substituted by a secondary amine group having at leat one of alkyl groups. The method of the present invention is a method for alkylation of 1,3,5-triazine derivatives, characterized by reacting 1,3,5-triazine derivatives (melamines, melamine derivatives, various kinds of guanaminde derivatives, etc.) which has at least one or more amino groups or mono-substituted amino groups on carbon atom of the ring thereof, with aldehydes or ketones alcohols in the presence of a catalyst of a metal of group VII and/or group VIII in the periodic table and a hydrogen-containing gas to alkylate said at least one of amino groups or mono-substituted amino groups. These derivatives are widely used as intermediates of fine chemicals such as agricultural chemicals, medications, dyestuffs, paints and the like and are widely used resin materials and as flame-retardant materials.

  本发明的目的是提供一种高产率生产取代的-1,3,5-三嗪衍生物的方法，在这种衍生物中，其环上至少有一个碳原子被至少有一个烷基的仲胺基取代。 本发明的方法是 1,3,5-三嗪衍生物的烷基化方法，其特征是将 1,3,5-三嗪衍生物（三聚氰胺、三聚氰胺衍生物、各种胍衍生物等）与至少具有一个或多个烷基的 1,3,5-三嗪衍生物（三聚氰胺、三聚氰胺衍生物、各种胍衍生物等）反应。其特征是：在元素周期表中第 VII 族和/或 VIII 族金属和含氢气体催化剂的存在下，将环的碳原子上至少有一个或多个氨基或单取代氨基的 1,3,5-三嗪衍生物（三聚氰胺、三聚氰胺衍生物、各种鸟苷酸衍生物等）与醛或酮醇反应，使上述至少一个氨基或单取代氨基烷基化。 这些衍生物被广泛用作精细化工产品的中间体，如农药、药物、染料、油漆等，也被广泛用作树脂材料和阻燃材料。
• Carbamoyl substituted oxazoles as thromboxane receptor antagonists
  申请人：ELI LILLY AND COMPANY

  公开号：EP0811621A2

  公开（公告）日：1997-12-10

  This invention relates to carbamoyl substituted heterocycles which are ω-phenyl-ω-(3-pyridyl)-ω-alkenoic acid derivatives bearing a carbamoyl substituted oxazolyl or oxazolinyl group on the phenyl ring and which demonstrate utility for thromboxane receptor antagonism and/or thromboxane synthase inhibition, as well as pharmaceutical formulations containing them, methods for their use, and processes and intermediates for their preparation.

  本发明涉及氨基甲酰基取代的杂环，这些杂环是ω-苯基-ω-(3-吡啶基)-ω-烯酸衍生物，在苯基环上带有氨基甲酰基取代的噁唑基或噁唑啉基，具有血栓素受体拮抗和/或血栓素合成酶抑制作用，还涉及含有这些杂环的药物制剂、使用方法以及制备这些杂环的工艺和中间体。
• Preparation of substituted alkenoic acids
  申请人：ELI LILLY AND COMPANY

  公开号：EP0816361A2

  公开（公告）日：1998-01-07

  This invention relates to a highly selective process for preparation of E-ω-phenyl-ω-(3-pyridyl)-ω-alkenoic acid derivatives bearing a carbamoyl substituted oxazolyl or oxazolinyl group on the phenyl ring which demonstrate utility for thromboxane receptor antagonism and/or thromboxane synthase inhibition, as well as to intermediates therefor.

  本发明涉及一种制备 E-ω-苯基-ω-(3-吡啶基)-ω-烯酸衍生物的高选择性工艺，该衍生物在苯基环上带有氨基甲酰基取代的噁唑基或噁唑啉基，可用于血栓素受体拮抗和/或血栓素合成酶抑制，本发明还涉及其中间体。